0001209191-17-047896.txt : 20170807 0001209191-17-047896.hdr.sgml : 20170807 20170807163923 ACCESSION NUMBER: 0001209191-17-047896 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170803 FILED AS OF DATE: 20170807 DATE AS OF CHANGE: 20170807 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kaye Edward M. MD CENTRAL INDEX KEY: 0001522780 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14895 FILM NUMBER: 171012040 MAIL ADDRESS: STREET 1: 3450 MONTE VILLA PARKWAY CITY: BOTHELL STATE: WA ZIP: 98011 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc. CENTRAL INDEX KEY: 0000873303 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930797222 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-274-4000 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Sarepta Therapuetics, Inc. DATE OF NAME CHANGE: 20120712 FORMER COMPANY: FORMER CONFORMED NAME: AVI BIOPHARMA INC DATE OF NAME CHANGE: 19980930 FORMER COMPANY: FORMER CONFORMED NAME: ANTIVIRALS INC DATE OF NAME CHANGE: 19970123 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-08-03 0 0000873303 Sarepta Therapeutics, Inc. SRPT 0001522780 Kaye Edward M. MD 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 1 0 0 0 Common Stock 2017-08-03 4 M 0 35461 A 87932 D Common Stock 2017-08-03 4 F 0 16703 37.88 D 71229 D Restricted Stock Units 2017-08-03 4 M 0 35461 0.00 D Common Stock 35461 0 D Restricted stock units convert into common stock on a one-for-one basis. Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock units granted on March 3, 2017. On March 3, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units. /s/David Tyronne Howton, as Attorney-in-Fact for Edward M. Kaye 2017-08-07